IPSC insider sale: CEO disposes 32,456 shares at $0.454

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) reported an insider transaction by its President and CEO, who is also a director of the company. On 11/17/2025, the reporting person sold 32,456 shares of common stock at a price of $0.454 per share.

According to the explanation provided, these sales represent shares sold to cover tax withholding obligations arising from the vesting of restricted stock units and were described as automatic, not at the discretion of the reporting person. After this transaction, the reporting person beneficially owned 3,236,453 shares of Century Therapeutics common stock, held directly.

Insider Trade Summary

Net Seller: 32,456 shares

Net Sell 1 txn

Insider Pfeiffenberger Brent

Role President and CEO

Sold 32,456 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Common Stock	32,456	$0.454	$15K

Holdings After Transaction: Common Stock — 3,236,453 shares (Direct)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/19/2025 - 04:19 PM Learn about SEC filing dates

FAQ

What insider transaction did Century Therapeutics (IPSC) report?

Century Therapeutics (IPSC) reported that its President and CEO, who is also a director, sold 32,456 shares of common stock on 11/17/2025.

At what price were the IPSC shares sold in this Form 4 filing?

The 32,456 shares of Century Therapeutics common stock were sold at a price of $0.454 per share.

Why did the IPSC executive sell 32,456 shares of stock?

The filing states that the sales represent shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units and were automatic.

How many Century Therapeutics (IPSC) shares does the reporting person own after the sale?

Following the reported transaction, the reporting person beneficially owned 3,236,453 shares of Century Therapeutics common stock, held directly.

What is the reporting person’s role at Century Therapeutics (IPSC)?

The reporting person is identified as both a Director and an Officer, serving as President and CEO of Century Therapeutics, Inc.

What is the purpose of this Form 4 for Century Therapeutics (IPSC)?

This Form 4 discloses a change in the beneficial ownership of Century Therapeutics common stock by its President and CEO, specifically a sale of 32,456 shares related to tax withholding on restricted stock unit vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		32,456	D	$0.454	3,236,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.